Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333206 | 1.00 | MAPT (0.36) | MAPTALDH1A1CYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL4585228 | 0.82 | SMN1; SMN2 (0.39) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4585219 | 0.82 | SMN1; SMN2 (0.39) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4585225 | 0.82 | SMN1; SMN2 (0.39) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6334992 | 0.78 | ALDH1A1 (0.39) | MAPTALDH1A1CYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL6334993 | 0.78 | ALDH1A1 (0.39) | MAPTALDH1A1CYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL21329586 | 0.75 | MEN1 (0.39) | ALDH1A1MEN1KMT2AAPLNRCA12 | |
| SCHEMBL21330105 | 0.75 | MEN1 (0.39) | ALDH1A1MEN1KMT2AAPLNRCA12 | |
| SCHEMBL21329582 | 0.75 | MEN1 (0.39) | ALDH1A1MEN1KMT2AAPLNRCA12 | |
| SCHEMBL157669 | 0.75 | STAT3 (0.33) | ALDH1A1MEN1KMT2AAPLNRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939867-B2 | Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents | PFIZER INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050113578-A1 | Process for preparing substituted pyridines | PFIZER INC | 2005-05-26 | — | — | US | disclosed |
| US-6844441-B2 | Process for preparing substituted pyridines | PFIZER INC (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040133005-A1 | Process for preparing substituted pyridnes | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| EP-1138685-B1 | Process for preparing substituted pyridines | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6670480-B2 | Used as intermediate in synthesis of beta-adrenergic receptor agonists | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030114670-A1 | Process for preparing substituted pyridines | DOW ROBERT L (US) | 2003-06-19 | — | — | US | disclosed |
| US-6518431-B2 | Reacting 2,5-disubstituted pyridine with silalating agent | PFIZER INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020077478-A1 | Process for preparing substituted pyridines | DOW ROBERT L (US) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113578-A1 | Process for preparing substituted pyridines | ADRB1, ADRA1A, ADRB2 | MAPT 2997/4885ALDH1A1 784/4885CYP2D6 292/4885 |
| US-20020077478-A1 | Process for preparing substituted pyridines | ADRB1, ADRA1A, ADRA1D | MAPT 3632/4885ALDH1A1 641/4885CYP2D6 242/4885 |
| US-20040133005-A1 | Process for preparing substituted pyridnes | ADRA1A, ADRB1, ADRA1B | MAPT 3808/4885ALDH1A1 550/4885CYP2D6 271/4885 |
| US-20020128247-A1 | Beta3 agonists and uses thereof | ADRB3, ADRB1, ADRB2 | MAPT 4302/4885ALDH1A1 764/4885CYP2D6 1970/4885 |
| US-20030114670-A1 | Process for preparing substituted pyridines | ADRB1, ADRA1A, ADRA1D | MAPT 3489/4885ALDH1A1 637/4885CYP2D6 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.